Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study.

ABSTRACT:

Background and aims

Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as an induction therapy in pediatric UC or IBD-U.

Methods

In this multicenter retrospective study, children treated with upadacitinib for induction of remission of active UC or IBD-U from 30 centers worldwide were enrolled. Demographic, clinical, and laboratory data, as well as adverse events (AEs), were recorded at Week 8 post-induction.

Results

One hundred children were included (90 UC and 10 IBD-U, median age 15.6 [interquartile range 13.3-17.1] years). Ninety-eight were previously treated with biologic therapies, and 76 were treated with ≥2 biologic

SUBMITTER: Yerushalmy-Feler A 

PROVIDER: S-EPMC12548835 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature